IJMS, Vol. 19, Pages 177: Fusion Proteins of NKG2D/NKG2DL in Cancer Immunotherapy

IJMS, Vol. 19, Pages 177: Fusion Proteins of NKG2D/NKG2DL in Cancer Immunotherapy

International Journal of Molecular Sciences doi: 10.3390/ijms19010177

Authors: Hui Ding Xi Yang Yanzhang Wei

NKG2D (natural killer group 2, member D) is an important activating receptor in natural killer (NK) cells and some T cells. NKG2D ligands (NKG2DLs) are specifically expressed on most tumor cells. The engagement of these ligands on tumor cells to NKG2D on NK cells will induce cell-mediated cytotoxicity and have target cells destroyed. This gives NKG2D/NKG2DLs great potential in cancer therapeutic application. The creation of NKG2D/NKG2DL-based multi-functional fusion proteins is becoming one of the most promising strategies in immunotherapy for cancer. Antibodies, cytokines, and death receptors have been fused with NKG2D or its ligands to produce many powerful fusion proteins, including NKG2D-based chimeric antigen receptors (CARs). In this article, we review the recent developments of the fusion proteins with NKG2D/NKG2DL ligands in cancer immunotherapy.

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2CNE7zm
via IFTTT